AMGN vs REPL · P/E 24, rev $36.75B vs $825.7M cap
Amgen Inc (AMGN) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported AMGN revenue for 2025-12-31 was $36.75B. Net income was $7.71B. Revenue was up 10.0% from 2024-12-31 to 2025-12-31. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
REPL does not have a complete income-statement cache yet.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. REPL currently screens at market cap $825.7M.
Not investment advice. Open the AMGN and REPL stock pages for the full models.
Not investment advice.